National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management

  • Emanuele Nicastri National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Nicola Petrosillo | nicola.petrosillo@inmi.it National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Tommaso Ascoli Bartoli National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Luciana Lepore National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Annalisa Mondi National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Fabrizio Palmieri National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Gianpiero D’Offizi National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Luisa Marchioni National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Silvia Murachelli National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Giuseppe Ippolito National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.
  • Andrea Antinori National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy.

Abstract

On January 9th, 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9th, 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data.

*for the INMI COVID-19 Treatment Group – ICOTREG

Abdeddaim A, Agrati C, Albarello F, Antinori A, Ascoli Bartoli T, Baldini F, Bellagamba R, Bevilacqua N, Bibas M, Biava G, Boumis E, Busso D, Camici M, Capobianchi MR, Capone A, Caravella I, Cataldo A, Cerilli S, Chinello G, Cicalini S, Corpolongo A, Cristofaro M, D’Abramo A, Dantimi C, De Angelis G, De Palo MG, D’Offizi G, De Zottis F, Di Lorenzo R, Di Stefano F, Fusetti M, Galati V, Gagliardini R, Garotto G, Gebremeskel Tekle Saba, Giancola ML, Giansante F, Girardi E, Goletti D, Granata G, Greci MC, Grilli E, Grisetti S, Gualano G, Iacomi F, Iannicelli G, Ippolito G, Lepore L, Libertone R, Lionetti R, Liuzzi G, Loiacono L, Macchione M,  Marchioni L, Mariano A, Marini MC, Maritti M, Mastrobattista A, Mazzotta V, Mencarini P, Migliorisi-Ramazzini P, Mondi A, Montalbano M, Mosti S, Murachelli S, Musso M, Nicastri E, Noto P, Oliva A, Palazzolo C, Palmieri F, Pareo C, Petrone A, Pianura E, Pinnetti C, Pontarelli A, Puro V, Rianda A, Rosati S, Sampaolesi A, Santagata C, Scarcia D’Aprano S, Scarabello A, Schininà V, Scorzolini L, Stazi GV, Taibi C, Taglietti F, Tonnarini R, Topino S, Vergori A, Vincenzi L, Visco-Comandini U, Vittozzi P, Zaccarelli M, Zaccaro G.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-03-16
Info
Issue
Section
Expert opinion
Keywords:
COVID-19, SARS-CoV-2, Treatment
Statistics
  • Abstract views: 11820

  • PDF: 9004
  • Supplementary Tables: 553
  • HTML: 123
How to Cite
Nicastri, E., Petrosillo, N., Ascoli Bartoli, T., Lepore, L., Mondi, A., Palmieri, F., D’Offizi, G., Marchioni, L., Murachelli, S., Ippolito, G., & Antinori, A. (2020). National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management. Infectious Disease Reports, 12(1). https://doi.org/10.4081/idr.2020.8543